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Abstract 
Human olfactory mucosa cells (hOMCs) have potential as a regenerative therapy for spinal cord injury. 
In our earlier work we derived PA5 cells, a polyclonal population that retains functional attributes of 
primary human OMCs. Microcarrier suspension culture is an alternative to planar 2D culture to 
produce cells in quantities that can meet the needs of clinical development. This study aimed to screen 
the effects of 10 microcarriers on PA5 hOMCs yield and phenotype. Studies performed in well plates 
led to a 2.9-fold higher cell yield on Plastic compared to Plastic Plus microcarriers with upregulation of 
neural markers β-III tubulin and nestin for both conditions. Microcarrier suspension culture resulted in 
concentrations of 1.4x105 cells/mL and 4.9x104 cells/mL for Plastic and Plastic Plus, respectively, after 
7 days. p75NTR transcript was significantly upregulated for PA5 hOMCs grown on Plastic Plus 
compared to Plastic. Furthermore, co-culture of PA5 hOMCs grown on Plastic Plus with a neuronal 
cell line (NG108-15) led to increased neurite outgrowth. This study shows successful expansion of PA5 
cells using suspension culture on microcarriers, and it reveals competing effects of microcarriers on 
cell expansion versus functional attributes, showing that designing scalable bioprocesses should not 
only be driven by cell yields. 
Key words: human olfactory mucosa cells, spinal cord injury, allogeneic cell therapy, microcarrier, 
suspension culture  
Introduction 
250,000 to 500,000 people are affected by spinal cord injury every year worldwide (Bickenbach et al., 
2013). The spinal cord is part of the central nervous system (CNS), and unlike the peripheral nervous 
 This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
 
system (PNS), has limited regenerative capacity after injury (Ahuja et al., 2017). The slow regenerative 
capacity of the CNS is attributed to the generation of a “glial scar” after injury which constitutes a 
barrier for axonal regrowth. Human olfactory mucosa cells (hOMCs) have shown promising results in 
both pre-clinical and clinical studies for the treatment of spinal cord injury (SCI) (F. Féron et al., 2005; 
Iwatsuki et al., 2008; Mackay-Sim et al., 2008; Tabakow et al., 2013). The regenerative capacity of 
OMCs is attributed to their unique ability to support the regeneration of olfactory receptor neurons 
(ORNs) which extended their axons from the PNS to the CNS, a property unique to the olfactory 
system in mammals (R. Doucette, 1991). The hOMC population can be obtained through biopsies of 
the olfactory mucosa, a source safer than the olfactory bulb which requires invasive intracranial surgery 
to be accessible (François Féron et al., 1998; Jani & Raisman, 2004). After biopsy, the cell population 
is subjected to a differential adhesion step to enrich neuroprotective cell types such as OECs, late 
adherent primary hOMCs, by removing rapidly adherent cells (i.e. fibroblasts) considered to be 
contaminants (Santiago-Toledo et al., 2019, Nash et al 2001). Early and recent studies have attributed 
the neural regeneration of the hOMC population to the presence of several different cell types, such as 
neural stem cells (NSCs), mesenchymal stem cells (MSCs), olfactory neurons and olfactory 
ensheathing cells (OECs), a type of glia (Delorme et al., 2010; J. R. Doucette, 1984; Lindsay et al., 
2013; Wolozin et al., 1992). Markers reported in hOMCs primary populations include glial (p75NTR, 
GFAP and S100β), neural stem cell (nestin), early neural differentiation (β-III tubulin), mesenchymal, 
and fibroblast associated markers (CD90/Thy1 and fibronectin) (Au et al., 2002; Bianco et al., 2004; 
Hahn et al., 2005; Kawaja et al., 2009). 
Reported clinical trials have used an autologous approach which can lead to variable outcomes. Since 
hOMCs populations are highly variable between patients, these are challenging to expand and there is a 
lack of consistency between protocols used for tissue biopsy and preparation of cells for transplant (F 
Féron et al., 1999). Therefore, it would be beneficial to develop an allogeneic or universal “off-the-
shelf” approach. We previously reported the generation of a candidate cell line from late-adherent 
hOMCs by genetic modification of primary cells with c-MycERTAM conditional immortalization 
technology, to advance a potential allogeneic therapeutic product for the treatment of SCI denominated 
PA5 hOMCs (Santiago-Toledo et al., 2019). It is yet unclear whether a unique cell type within a 
hOMCs population is responsible for neural regeneration, or whether there is benefit in transplanting 
several types of cells within the population (Anna et al., 2017; Reshamwala et al., 2019). Clones from 
polyclonal populations such as PA5 hOMCs can be further derived, expanded, banked and screened to 
generate an allogeneic cell therapy product for the treatment of SCI. The generation of a conditionally-
immortalized hOMC population, such as PA5 hOMCs, enables a potentially extended life span, 
allowing the application of a cell-banking model-based manufacturing process, necessary for an 
allogeneic cell therapy. 
The translation of such a therapeutic product to the market would require the development of a scalable 
bioprocess, able to yield large amounts of cells which can reach doses up to 1x107 cells/dose (Casarosa 
et al., 2014). Commonly, adherent or anchorage-dependent cells have been grown in two-dimensional 
platforms such as tissue-culture flasks, cell factories and automated systems. Even though these 
systems are reliable due to their wide spread use in the industry, they are not easily scalable for 
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producing large quantities of allogeneic cells, making them unsuitable for commercial stages 
(Brandenberger et al., 2011; Simaria et al., 2014). Among available technologies, microcarriers are a 
suitable alternative to perform expansion of adherent cells in a scalable manner in stirred tank 
bioreactors and offer a higher larger surface per unit volume of bioreactor. It may be feasible to 
manufacture early-stage clinical products using planar systems and then transition to stirred tank 
bioreactors for late-stage clinical trials and commercialisation, yet this would require significant 
validation work to meet regulatory approval, and risk product specification failure later in development 
due to manufacturing process changes. Therefore, early adoption of market scale manufacturing 
technology is necessary. 
Microcarrier cell culture platforms have been reported for the successful expansion of mesenchymal 
stem cells (MSCs) (dos Santos et al., 2014; Rafiq et al., 2013), embryonic stem cells (ESCs) (Oh et al., 
2009) and induced pluripotent stem cells (iPSCs) (Badenes et al., 2017; Carlos AV Rodrigues et al., 
2018). Stirred tank bioreactors are well explored systems that enable the monitoring and control of 
several culture parameters such as oxygen tension, pH and agitation regimes. These platforms also 
offer a closed bioprocess environment with reduced operator interference and variability. Therefore, 
these are platforms that offer more robust and reproducible bioprocesses that theoretically can deliver 
consistent quality products, compliant with Good Manufacturing Practice (GMP) and Good Clinical 
Practice (GCP) requirements. 
In this work, we report the microcarrier expansion of a candidate cell population for the treatment of 
SCI, PA5 hOMCs, on microcarrier stirred culture using spinner flasks, with the aim to identify a 
microcarrier type that maximize the expansion of neuroprotective cell types such as OECs, NSCs, and 
MSCs, which can lead to increased potency. First, a variety of commercially available microcarriers 
were selected based on a screening methodology using ultra-low attachment 96-well plates. Besides the 
suitability of the microcarrier, considerations of compliance for good manufacturing practices (GMP) 
and adaptability to xeno-free conditions were considered for microcarriers selection. Then, cells were 
grown on two types of microcarriers using spinner flasks, based on protocols previously reported for 
the expansion of hMSCs (Santos et al., 2011). To further understand growth kinetics, PA5 hOMCs 
were grown on microcarriers for 7 days. Cell phenotype was assessed through immunocytochemistry 
and RT-qPCR. Potency of PA5 hOMCs was assessed through the capacity of the harvested cells to 
promote neurite outgrowth using a co-culture assay of hOMCs and NG108-15 neurons. 
We report the use of a microcarrier-based spinner flasks system for the expansion of the PA5 hOMCs 
population of cells, a candidate cell line for the treatment of spinal cord-injury. 
Materials and methods 
hOMC monolayer culture 
PA5 hOMCs were expanded in T-flasks, freshly coated with poly-L-lysine (PLL, Sigma, UK, 100 
μg/mL), using as complete medium DMEM/F12 + GlutamaxTM (Gibco, Life Technologies, UK) 
supplemented with 10% fetal bovine serum (FBS) (Sigma, Germany) and 4-hydroxitamoxifen (4-
OHT’, 1:10,000). Cells were maintained in a standard incubator (37⁰C, 5% CO2 in air). A seeding 
density of 6000 cells/cm2 was used and feeding was performed every two days. Cells were passaged 
when 60-80% confluency was reached, through incubation with TryPLE (Gibco, UK) for 5 minutes. 
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The dissociation reagent was quenched with complete medium and the cell suspension was centrifuges 
for 5 minutes at 400 x g. 
Microcarrier screening in well plates 
10 commercially available microcarriers were tested for expansion of PA5 hOMCs in ultra-low 
attachment 96-well plates: Plastic, Plastic Laminin Coated (Plastic L), Plastic Plus, PronectinF®, 
Collagen, FACT III, Star-Plus, Hillex II, all from Pall, UK. Synthemax II ® (Low and High 
Concentration) (Corning, UK) and Cytodex I (GE Healthcare, UK) were also used. Microcarriers 
specifications are shown on Table 1. Sterilization of Pall microcarriers and Cytodex I microcarriers was 
achieved by resuspension in distilled water (Gibco, UK) and PBS Ca+ and Mg+ free (Lonza, UK), 
respectively, followed by autoclaving at 121 ºC for 15 min. Synthemax II ® microcarriers were 
sterilized under a UV lamp for 90 minutes. 
A monolayer of microcarriers with a total surface area of 1.28 cm2 was used per well, in order to cover 
the bottom of a 96-well plate well. For 6-well plates, a monolayer of microcarriers with a total surface 
area of 38 cm2 was used per well. Total working volumes were of 200 µL and 6 mL for 96-well plates 
and 6-well plates, respectively. Plastic L microcarriers were incubated with a solution of 20 µg/mL 
Cultrex ® Mouse Laminin I (Trevigen, UK) for 1 hour in a standard incubator prior to cell seeding. All 
microcarriers were let to equilibrate for 1 hour in a standard incubator with complete medium. A 
seeding density of 6000 cells/cm2 was used. Medium exchanges were performed for 50% of the total 
volume, every two days. Cells were culture in ultra-low 96-well plates for a total of 7 days. For 96 
well-plates, relative viable cell number was measured using the cell Counting Kit-8 (CCK-8) (Dojindo, 
Japan) every time medium exchanges were performed. Briefly, 10 µL of reagent were added per 100 
µL of microcarrier suspension. After incubation for 1 hour in a standard incubator, the supernatant was 
transferred to a 96-well plate and absorbance readings at 450 nm were performed in a microplate reader 
(Tecan, Switzerland). Quantification of the of cells per well was performed based on a standard curve 
performed on the first day of culture. 
Spinner-flask culture 
The protocol used for spinner flask culture was based on Santos et al 2011. Suspension culture 
experiments were performed in 100-mL flat bottom spinner-flasks (Bellco) with 80 mL as working 
volume. Spinner-flasks were siliconized using Sigmacote (Sigma, Germany) to avoid cell attachment. 
After applying the reagent to all the glass surface and aspirating it, vessels were let to dry for 24 hours 
in a fume hood. After, vessels were rinsed three times with distilled water (Gibco, UK). Plastic and 
Plastic Plus microcarriers were used for spinner-flask culture with a total surface area of 518.4 cm2. 
Microcarriers were prepared by autoclaving in distilled water (Gibco, UK) for 121 ºC for 15 min. 
After, the distilled water was aspirated as much as possible and complete medium was added. 
Microcarriers were let to equilibrate for 1 hour in a standard incubator. 60-80% confluent PA5 hOMCs 
were detached as described in section “hOMC cell culture” and an adequate amount of cells was added 
to the tube containing the microcarriers suspension in complete medium to a seeding density of 6000 
cells/cm2. After transferring the microcarrier and cell suspension to spinner-flasks containing adequate 
amounts of complete medium, an agitation of 40 rpm was started. Spinner-flasks were maintained on a 
Bell-EnniumTM Compact 5 position magnetic stirrer platform (BellCo) in a standard incubator. In order 
to allow for air exchange, a side-arm of the spinner-flask was kept loosened (half a turn of the cap). 
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Cell expansion was maintained for 7 days. Feeding was performed every two days by removing 50% of 
the expanded medium and adding the same amount of fresh complete medium. Sampling, also 
performed every two days, was achieved by retrieving 2 mL of a homogeneous microcarriers 
suspension for manual cell counting and immunocytochemistry. Cell counting and viability 
measurements were performed by trypan blue exclusion, using a haemocytometer. 
Harvest  
Exhausted medium was retrieved from the vessel and the microcarrier-cell suspension was washed with 
40 mL of HBSS (Gibco, UK) twice. 20 mL of TryPLE Select (Gibco, UK) were incubated with the 
microcarrier-cell suspension for 15 minutes, at an agitation of 100 rpm in a standard incubator. To 
quench the dissociation reagent, 30 mL of complete medium were added. The suspension was passed 
through 40 µm cell strainers and centrifuged for 5 minutes at 400 xg. Harvested cells were counted 
using the trypan blue exclusion method and were either pelleted for RT-qPCR or plated at 6000 
cells/cm2 to perform several assays such as immunocytochemistry and NG108-15 co-culture assay.  
Analytical techniques  
Metabolite analysis 
On the days medium exchange occurred, metabolite analysis was performed using the the CuBian 
HT270 analyzer (Optocell GmbH & Co, KG, Germany to obtain the concentration of glucose, lactate 
and ammonia. 
Immunocytochemistry 
Samples were fixed using a solution of 4% PFA in PBS for 20 minutes at RT. After washing with PBS 
(Lonza) for 5 minutes, twice, permeabilization was done through incubation of samples with a solution 
of 0.1% Triton X-100 (Sigma) in PBS for 20 minutes at room temperature. After washing samples 
twice with PBS for 5 minutes, samples were incubated with a blocking solution of 5% Goat Serum 
(DAKO) in PBS for 1 hour at room temperature. Primary antibodies against p75NTR (Millipore), 
fibronectin (Sigma), CD90 (Millipore), nestin (Millipore), GFAP (Dako), S100β (Dako) and β-III 
tubulin (Sigma) (Table 2) were used with a dilution of 1:200 in blocking solution and incubated for 90 
minutes at room temperature. After washing with PBS, secondary antibodies (Goat anti-rb IgG (H+L)-
Alexa Fluor 594; Goat anti-Ms (H+L)-Alexa Fluor 488, Invitrogen) and Hoechst 33342 (Molecular 
Probes) were diluted in blocking solution using a dilution of 1:200 and 1:1000, respectively. Images of 
planar culture were acquired using the microscope system EVOS® FL (ThermoFisher Scientific), while 
microcarrier culture 16-bit multi-color montage images were obtained with a Zeiss LSM 880 with 
Airscan confocal microscope system (Carl Zeiss) and Zen 2009 acquisition software (Carl Zeiss).  
qRT-PCR 
Cells expanded on microcarriers in ultra-low attachment 6-well plates were detached as previously 
described. Cell suspensions were centrifuged and excess medium was removed prior to storage at -
80oC until further analysis. Pellets were first re-suspended in RLT Buffer (QIAGEN) before being 
homogenised in Qiashredder Columns (QIAGEN) according to the manufacturer’s instructions. 
Synthesis of complementary deoxyribonucleic acid (cDNA) and removal of genomic DNA was 
performed using the QIAGEN RT-PCR kit following the manufacturer’s instructions. Genomic DNA 
was eliminated using gDNA Wipeout Buffer (QIAGEN) with up to 1 µg template RNA and RNAse 
free water in a total reaction volume of 14 µL. The entire 14 µL reaction volume was subsequently 
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mixed with a MasterMix (Bio-Rad): template RNAs or no template for NTC (no template control), RT 
Primer Mix Quantiscript RT Buffer and Quantiscript Reverse Transcriptase or with RNA free water for 
no-RT (No reverse transcriptase control), in a total volume of 20 µL. The qPCR reactions were 
performed in Bio-Rad Hard-Shell Low Profile Thin-Wall 96 Well Skirted PCR plates on the Bio-Rad 
CFX 96 Connect Real-Time PCR System using the Quantitect SYBR Green PCR Kits (QIAGEN) 
according to the manufacturer’s instructions. For each reaction Quantitect Mastermix Buffer, 
Quantitect pre-validated primer assay (Table 2), water and cDNA were combined to make final 
reaction volumes of 25 µL. On each 96-well plate samples were analysed in triplicate with β-actin as an 
internal reference control and standard controls No-RT and NTCs to check for cross contamination. 
The 2-ΔΔCt method was used to analyse the data. 
Co-culture assay 
A co-culture of NG108-15 neurons with PA5 cells after expansion on microcarriers was used to assess 
neuron outgrowth. NG108-15 cells (ATCC HB-12317) are a hybrid rodent glioma-neuroblastoma cell 
line. As a positive control, a rat SCL 4.1/F7 (ECACC 93031294) Schwann cell line was used. 
NG108-15 and F7 cells were grown for two passages on T-flasks coated with poly-L-lysine (PLL, 
Sigma, 100 µg/mL) or uncoated, respectively. When 60-80% confluency was reached, NG108-15 cells 
were passaged by hitting the flask and re-plated at 6000 cells/cm2, while F7 cells were passaged 
following the same protocol used for PA5 hOMCs and re-plated at 6000 cells/cm2. For the co-culture 
assay PA5 hOMCs were plated at 6000 cells/cm2 onto freshly coated 24-well plates with poly-L-lysine 
(PLL, Sigma, 100 µg/mL). After 24 hours, NG108-15 cells were plated on wells with PA5 hOMCs or 
F7 cells using a seeding density of 500 cells/well. Medium changes were performed every two days 
and samples fixed after 5 days. 4-OHT was not added in the medium for this assay. 
Immunocytochemistry was performed as previously described. Images were acquired with EVOS FL 
Imaging System (Thermo-Scientific) at a 100x total magnification. 15 frames were acquired per 
condition (5 per technical repeat) and neurite quantification was performed manually using the NeuronJ 
(Meijering et al., 2004) plugin in ImageJ. 
Statistical methods 
The Kolmogorov-Smirnov test was used for data normality and Levene's test was used for 
homogeneity of variance. For pairwise-comparisons, one-way ANOVA was used with post-hoc 
Tukey's or Games-Howell test. A difference of p<0.05 was considered significant. All tests were 
performed using OriginPro 2016 (OriginLab, USA).  
Formulae 
The specific growth rate, µ (day-1): ln(𝑋) =  𝜇𝑡 + ln (𝑋0) 
Where 𝑋 is the concentration of cells, 𝑋0 is the concentration of cells at 𝑡0. 𝜇 for the exponential phase, 
considered to be from day 3 to 7.  
Doubling time, 𝑡𝑑 (days): 
𝑡𝑑 = ln (2)𝜇  
Fold-increase: 
𝐹𝑜𝑙𝑑 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 =  𝑋𝑡
𝑋0
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Where 𝐶𝑋(𝑡) is the cell concentration at the end of the culture and 𝐶𝑋(0) is the initial cell concentration. 
Specific nutrient consumption and metabolite production rate, 𝑞𝑚𝑒𝑡 (pmol.cell
-1.day-1) 
𝑞𝑚𝑒𝑡 = 𝜇𝑋0 𝐶𝑚𝑒𝑡(𝑡) − 𝐶𝑚𝑒𝑡(0)𝑒𝜇𝑡 − 1  
Where 𝐶𝑚𝑒𝑡(𝑡) and 𝐶𝑚𝑒𝑡(0) are the concentration of metabolite at the end and start of the exponential 
phase.  
Lactate yield from glucose, YLac/Glc 
𝑌𝐿𝑎𝑐/𝐺𝑙𝑐 = ∆[𝐿𝑎𝑐]∆[𝐺𝑙𝑐] 
Where ∆[𝐿𝑎𝑐] is the lactate production and ∆[𝐺𝑙𝑐] is the glucose consumption during the exponential 
phase. 
Results 
PA5 hOMCs planner cell culture 
PA5 hOMCs were cultured on a monolayer at a seeding density of 6,000 cells/cm2 for 7 days in 96-
well plates. Viable cell counts, performed with the CCK-8 viability reagent, showed increased growth 
over time, with the highest number of viable cells of 5.5×104 reached by day 7 (Figure 1 A). 
Morphologically, PA5 hOMCs showed an elongated, fibroblastic like shape (Figure 1 B). Cells stained 
positive for the glial markers p75NTR, S100β, and GFAP which are commonly used to characterise the 
OEC phenotype (Au et al., 2002; Bianco et al., 2004; Hahn et al., 2005; Kawaja et al., 2009). PA5 
hOMCs stained positive for other markers, such as nestin and β-III tubulin, associated with the 
neuronal phenotype (Gómez-Virgilio et al., 2018; Murrell et al., 2005). The population also stained 
positive for fibronectin (fibroblast marker) (Ito et al., 2006; Yiu & He, 2006) and CD90 (MSC marker) 
(C. Chen et al., 2014; Holbrook et al., 2011). 
Microcarrier screening for PA5 hOMCs growth on well plates 
The growth of PA5 hOMCs was tested on 10 commercially available microcarriers in ultra-low 
attachment 96-well plates. The growth of PA5 hOMCs was followed over 7 days as this is the length of 
time for the duration of one passage (Figure 2 A). After seeding on day 0, viable cell number was 
measured every two days, when media was exchanged. On day 1, viable cell numbers ranged from 
8.1x103 cells/well to 9.6x103 cells/well for Plastic LC, Synthemax II LC, Synthemax II HC, Plastic, 
Plastic Plus and FACT II (Figure 2 B). At the same time point, Star-Plus and Cytodex I microcarriers 
provided a viable cell number between 3.3x103 to 5.0x103 cells/well. As shown in Figure 2 C, by day 7, 
three distinct groups of microcarriers were observed. Plastic and Collagen microcarriers supported high 
growth of 8.8x104 and 7.5x104 cells/well. Plastic L, Synthemax II LC, Synthemax II HC, Collagen, 
PronectinF, FACT III and Cytodex I performed similarly between each other, yielding between 4.5x104 
and 6.4x104 cells/well. Plastic Plus and Star-Plus microcarriers yielded low cell numbers, lower than 
3.0x104 cells/well. All microcarriers except Star-Plus led to increase cell number across the days of 
culture, where after day 3 there was an increase in cell number/well (Figure 2 A). 
A second experiment was performed using ultra-low attachment 6-well plates using an increased 
working volume but maintaining scalable parameters. The number of microcarriers per well surface 
and the same initial seeding density of 6000 cells/cm2 were used. Haemocytometer counts were 
performed to measure viable cell density on day 7 and phenotypic changes were assessed through RT-
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qPCR. Plastic microcarriers led to the highest cell numbers (1.7±0.1x106 cells/mL), while Plastic Plus 
led to the lowest numbers (7.5±0.4x105 cells/mL) (Figure 3 A). Cell viability analysis revealed >95% 
viability of PA5 hOMCs on all microcarriers tested (Figure 3 B). Metabolite analysis of glucose, lactate 
and ammonium were performed on day 7 (Figure 3 C, D and E). Glucose concentrations were all 
between 4 - 8.5 mM, with Plastic showing the lower concentration and Plastic Plus the highest. The 
opposite trend was seen for lactate concentration with values between 12 - 16.5 mM. The concentration 
of ammonia was similar between all conditions with 0.8 mM for all microcarriers, except for Plastic 
microcarriers which produced a concentration of 0.65±0.1 mM. The phenotype of PA5 hOMCs was 
investigated using RT-qPCR. It is known that the olfactory mucosa population of cells harbours a mix 
of different cell types including mesenchymal stem cells, neural stem cells, fibroblasts and olfactory 
ensheathing cells (OECs). The OEC phenotype has been characterised by the expression of the glial 
markers p75NTR, S100β, GFAP and the neural stem cell marker nestin and early neural differentiation 
marker β-III tubulin. Fibronectin has been used as a marker of ‘contaminating’ cell types as it can 
indicate the presence of fibroblasts. Results show the upregulation of neural stem cell markers β-III 
tubulin for Plastic L, Plastic and Plastic Plus microcarriers by 2-fold, and nestin for Plastic and Plastic 
Plus by 1.6-fold (Figure 3 F). Given the phenotypic traits obtained for cells grown in ultra-low 
attachment in 6 well-plates, with the objective to create a scalable bioprocess, Plastic and Plastic Plus 
were subsequently used to grow PA5 hOMCs in agitated cell culture conditions in spinner flasks.  
Expansion of hOMCs in microcarriers suspension culture using spinner-flasks 
PA5 hOMCs growth and metabolic profile in cell cultures using Plastic and Plastic Plus 
microcarriers 
A method previously developed by Santos et al 2011 was adopted to performed PA5 hOMCs 
microcarrier cell culture in spinner flasks. A total working volume of 80 mL in 100-mL Belco spinner 
flasks was used with 50% of media change every two days, for a total of 7 days. An initial seeding 
density of 6000 cells/cm2 was used, which is equivalent to 3.4x104 cells/mL. Figure 4 A shows that 
both Plastic and Plastic Plus microcarrier cultures experienced a decrease in cell concentration after day 
1 from 3.4±0.03x104 cells/mL to 1.4±0.3x104 cells/mL and 9.4±1.3x103 cells/mL, respectively. Cell 
number started increasing after day 3. On day 7, the concentration of cells in cultures employing Plastic 
microcarriers was 1.4±1.1x105 cells/mL and for Plastic Plus microcarriers was 4.9±1.8x104 cells/mL 
(statistically significant, p<0.05). Cell viability remained above 90% (Figure 4 A) throughout the 
culture period. Representative images of Hoechst-counterstained PA5 hOMCs attached on Plastic and 
Plastic Plus microcarriers for each day of sample show cells were expanding on the microcarriers 
(Figure 4 E). Moreover, PA5 cells were completely detached from the microcarriers following the 
harvest in a gentle dissociation reagent and agitated conditions with high viability (Figure 4 F). 
Metabolic analysis of glucose, lactate and ammonia revealed similar concentration of these nutrient and 
metabolites for both conditions (Figure 4 B-D). On day 7, glucose concentration was of 10.5±1.7 mM 
and 11.5±1.6 mM, while lactate concentration was of 7.3±2.3 mM to 5.2±2.5 mM, for PA5 hOMCs 
grown on Plastic and Plastic Plus, respectively. The concentration of ammonia was of 0.7 mM for both 
conditions. Considering an exponential phase starting on day 3, specific consumption of glucose, 
specific production of lactate and ammonia, as well as yield of lactate per glucose were calculated. PA5 
hOMCs grown of Plastic Plus led to a specific glucose consumption rate of 24.4±2.3 pmol.day-1cell-1, 
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similar to the one measure for PA5 hOMCs grown on Plastic which was 20.4±4.7 pmol.day-1cell-1. 
Specific production rates for lactate and ammonia was 47.9±6.3 pmol.day-1cell-1 and 0.6±0.1 pmol.day-
1cell-1, respectively for PA5 hOMCs grown on Plastic Plus. These results were on average 2 times 
higher than the specific production rates observed for PA5 hOMCs grown on Plastic microcarriers 
(24.6±7.2 pmol.day-1cell-1 and 0.3±0.05 pmol.day-1cell-1 for lactate and ammonia, respectively). The 
yield of lactate per glucose was 1.4±0.4 and 2.0±0.3 for PA5 hOMCs grown on Plastic and Plastic Plus 
microcarriers, respectively.  
PA5 hOMCs phenotype and promotion of neuron outgrowth after growth on Plastic and Plastic 
Plus microcarrier suspension culture 
Immunocytochemistry was performed for characteristic hOMCs biomarkers as presented in Figure 5 
for PA5 hOMCs grown on Plastic and Plastic Plus microcarriers for 7 days. Immunocytochemistry 
results show the expression of p75NTR, GFAP, S100β (glial markers), β-III tubulin, nestin (neural 
markers), fibronectin (fibroblastic marker) on both Plastic and Plastic Plus microcarriers. RT-qPCR 
results (Figure 6 A and B), show the upregulation of several markers for PA5 hOMCs grown on Plastic 
Plus compared to cells at day 0. β-III tubulin (2.3-fold), Fibronectin (3.5-fold), KDR (2.9-fold) and 
Sox9 (2.9-fold) are upregulated for PA5 hOMCs grown on Plastic Plus microcarriers compared to PA5 
hOMCs grown on Plastic microcarriers by day 7. Most importantly, p75NTR, a neurotrophic marker 
expressed by OECs is expressed 2.3-fold more on day 7 by PA5 hOMCs grown on Plastic Plus 
microcarriers compared with cells on day 0, while PA5 hOMCS grown on Plastic microcarriers 
maintained the same level of expression of this marker (1.0-fold) (p<0.05). Furthermore, a co-culture 
assay with NG108-15 cells was used as an assay indicative of the capacity of PA5 hOMCs to promote 
neurite outgrowth, using F7 Schwan cells as positive control and NG108-15 cell only as a negative 
control. Representative images used to quantify neurite outgrowth are shown in Figure 5 C. The 
average neurite length was 36±1.3 µm for Plastic Plus microcarriers, significantly higher (p<0.05) than 
the average neurite length obtained for Plastic (29.1±1.5 µm) microcarriers and the positive control 
(27.9±0.1 µm) (Figure 5 D). The maximum neurite length obtained for Plastic Plus was 96±7.0 µm, 
significantly higher (p<0.05) than the maximum neurite length obtained for Plastic microcarriers 
(81.8±3.2 µm) and the positive control (57.9±3.3 µm) (Figure 5 E). The average neurite per neuron was 
of 0.38±0.05, significantly higher (p<0.05) than the one obtained for cells grown on Plastic 
microcarriers (0.23±0.02) and the positive control (0.22±0.04) (Figure 5 F).  
Discussion 
PA5 hOMCs are a potential candidate therapy for an allogeneic cell therapy for the treatment of spinal 
cord injury (Santiago-Toledo et al., 2019). High cell doses of up to 1 billion cells will be required to 
produce cell banks to be supplied to patients (Casarosa et al., 2014). It has been shown that stirred tank 
bioreactor cell culture using microcarriers is a reliable, reproducible method to achieve high numbers 
of cells in a scalable manner (Qiu et al., 2016; Rafiq et al., 2013; Carlos AV Rodrigues et al., 2018; 
Santos et al., 2011). The first step to develop such a production method would be to select the right 
type of microcarrier and several authors have shown the successful screening of microcarriers for the 
growth of MSCs and NSCs (T. Chen et al., 2011; Rafiq et al., 2016; Carlos A. V. Rodrigues et al., 
2011). Therefore, a similar strategy to those already presented for other cell types was used and in 
addition cell phenotype analysis was performed. PA5 hOMCs growth was followed for 7 days on 
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microcarriers using static 96-well plates. In terms of cell concentration after 7 days, while Plastic, 
Plastic L, Synthemax II LC, Synthemax II HC and PronectinF showed the most promising results, 
FACT III, Plastic Plus and Star-Plus microcarriers led to the lowest cell yields. Interestingly, it was 
observed that in spite of PA5 hOMCs efficiently attached to Plastic Plus microcarriers, the yield of 
cells on day 7 was lower than all other microcarriers with similar attachment efficiency (Plastic, Plastic 
L, Synthemax II LC, Synthemax II HC, and Collegen). This observation suggests that PA5 hOMCs 
grown on Plastic Plus microcarriers results in a slower growing population, in contrast with cells grown 
on neutrally charged surfaces. Interestingly, this has been reported for other anchorage-dependent cell 
types such as BM-MSCs (Rafiq et al., 2016). 
In order to further investigate the phenotype of PA5 hOMCs after 7 days of culture, static microcarrier 
cultures on ultra-low attachment 96-well plates were scaled up to ultra-low 6-well plates. Interestingly, 
RT-qPCR results show the upregulation of neural stem cell marker nestin and early neural 
differentiation marker β-III tubulin on Plastic and Plastic Plus microcarriers. Neural stem cells are a 
cell type present in the olfactory mucosa (Delorme et al., 2010; Murrell et al., 2005; Nash et al., 2001) 
and may therefore be regenerative constituents of the PA5 hOMC populations. The upregulation of 
nestin for cells grown on Plastic and Plastic Plus microcarriers could contribute to increased neural 
regeneration, and may have led to the survival of olfactory neurons, displaying the expression of β-III 
tubulin, an early neural differentiation marker. Furthermore, even though Plastic Plus microcarriers did 
not led to such an increase in cell number, positive surfaces have been used in the past to promote 
attachment of neuronal cell types that may lead to neural regeneration (Kozak et al., 1978). 
These results led to the selection of Plastic and Plastic Plus microcarriers for suspension culture in 
spinner flasks following a previously described method to grow hMSCs (Santos et al., 2011). Plastic L 
microcarriers were not taken into further studies due to the impracticality of in-house coating of 
microcarriers which is an additional expense and manipulation which would have to be considered in 
the manufacturing process. 
Suspension microcarrier culture of PA5 hOMCs was carried out for 7 days. After day 1, a drop in 
viable cell concentration was observed due to only around 70-75% of cells attaching for both 
conditions, indicating inefficient cell attachment. After day 3, cells in both conditions start to grow, 
however, lower cell expansion was observed on Plastic Plus microcarriers. Thus Plastic microcarriers 
may encourage expansion of faster growing clones. By day 7 significantly higher viable cell 
concentration is obtained for PA5 hOMCs grown on Plastic microcarriers compared to Plastic Plus 
microcarriers, showing comparable results to studies performed in ultra-low attachment well-plates. 
Even though lower amount of PA5 hOMCs was obtained on Plastic Plus microcarriers on day 7, 
compared to Plastic microcarriers, cultures produced similar concentrations of glucose, lactate and 
ammonia over time. The concentrations of ammonium and lactate were below the reported inhibitory 
levels for hMSCs of 35.4 mM and 5.8 mM, respectively (Schop et al., 2009). Therefore, it is unlikely 
that the concentration of lactate and ammonia had a negative impact on PA5 hOMCs growth, assuming 
that hOMCs and hMSCs share similar metabolic response properties. The specific consumption of 
glucose was similar for both cultures, while the production of lactate and ammonia was double the 
amount for PA5 hOMCs grown on Plastic Plus microcarriers. In this study, the yield of lactate from 
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glucose is close to 2 for PA5 hOMCs grown in both conditions, suggesting that glucose is metabolised 
through aerobic glycolysis. In aerobic glycolysis, in the presence of oxygen, glucose metabolism is 
shifted from OXPHOS to glycolysis (Jones & Bianchi, 2015). These results can be explained by the 
upregulation of LDH activity promoted by the presence of the oncoprotein c-Myc (Shim et al., 1998). 
The PA5 hOMCs population is genetically modified with a fusion gene, c-MycERTAM, activated by the 
synthetic estrogen-like agonist 4-hydrotamoxifen (Santiago-Toledo et al., 2019; Wall et al., 2016).  
Phenotype analysis performed through immunocytochemistry showed that expression of hOMCs 
characteristic biomarkers such as p75NTR, GFAP, S100β (glial markers), β-III tubulin, nestin (neural 
markers), fibronectin (fibroblastic marker) was maintained on both Plastic and Plastic Plus 
microcarriers after 7 days of expansion. Phenotype analysis was also assessed through RT-qPCR for 
PA5 hOMCs harvested at day 7 from Plastic and Plastic Plus microcarriers. Neurotrophin receptor 
p75NTR expression has been attributed to the presence of OECs, a slow adherent cell type present in the 
olfactory mucosa, which has been reported to promote neural regeneration (Franceschini & Barnett, 
1996; Pixley, 1992; Ramon-Cueto et al., 1993). Phenotypic analysis performed through RT-qPCR, 
revealed the upregulation of p75NTR more than 2.5-fold for PA5 hOMCs grown on Plastic Plus 
microcarriers compared to Plastic microcarriers, after day 7. Factors related to microcarrier surface 
such as charge and stiffness may have led to an increase in the expression of p75NTR for PA5 hOMCs 
grown on Plastic Plus microcarriers (Yang et al., 2017). The upregulation of β-III tubulin, although not 
statistically significant, might indicate the presence of a higher number of early neural differentiated 
cells or the promotion of survival of olfactory neurons on Plastic Plus microcarriers compared to 
Plastic microcarriers on day 7. 
PA5 hOMCs potency was assessed in terms of ability to promote neurite outgrowth in a co-culture 
assay with NG108-15 cells. Results reveal that PA5 hOMCs grown on Plastic and Plastic Plus 
microcarriers retained promising functional activity. Studies of PNS repair which employed this assay 
shown that neurite outgrowth in vitro can be associated with Schwann cell potency to enhance neurite 
length in vivo (Daud et al., 2012; Jonsson et al., 2013). 
The increased neurite outgrowth observed on NG108 co-culture assay using PA5 hOMCs grown on 
Plastic Plus microcarriers is likely to be related with the increased expression of p75NTR, a marker of 
OECs (Delorme et al., 2010; J. R. Doucette, 1984; Lindsay et al., 2013; Wolozin et al., 1992). 
Therefore it is hypothesized that Plastic Plus led to an enrichment of OECs, which were then 
responsible for the increase in neurite outgrowth on this condition. In order to fully elucidate the 
mechanism of action it will be necessary to subclone the PA5 hOMCs population. These clones will 
have to be phenotypically characterized through immunocytochemistry or flow cytometry, expanded 
and checked for potency using the NG108 co-culture assay as well as animal studies. 
In conclusion, we have demonstrated that expansion of PA5 hOMCs on Plastic and Plastic Plus 
microcarriers in suspension culture in agitated culture using spinner flasks is permissive. This study 
shows that expanding c-MycERTAM-derived hOMCs on Plastic Plus microcarriers leads to cells with 
increased potency and increased expression of p75NTR, a marker expressed by OECs. The work 
presented in this manuscript is a proof of concept that reveals competing effects of microcarriers on cell 
expansion versus functional attributes, showing that designing scalable bioprocesses should not only be 
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driven by cell yields, but also by phenotype and potency. This method contributes for the design of a 
bioprocess that in the future can support the expansion of clones of the PA5 hOMCs population in 
order to create an off-the-shelf advanced therapy for the treatment of CNS injuries such as those for the 
spinal cord. 
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Tables 
Table 1 - List of microcarriers used and respective properties. 
Microcarrier Manufacturer Diameter 
(µm) 
Matrix Surface 
coating/charge 
Average 
density 
Plastic Pall 125-212 Polystyrene None 1.02 
Plastic Laminin 
coated (Plastic L) 
Pall 125-212 Polystyrene Cultrex ® Mouse 
Laminin I 
1.02 
Plastic Plus Pall 125-212 Polystyrene Cationic surface 1.02 
PronectinF ® Pall 125-212 Polystyrene Recombinant 
Fibronectin 
1.02 
Collagen Pall 125-212 Polystyrene Type I porcine 
collagen 
1.02 
FACT III Pall 125-212 Polystyrene Type I porcine 
collagen 
1.02 
Star-Plus Pall 125-212 Polystyrene Cross-linked 
polystyrene 
1.02 
Hillex II Pall 160-200 Polystyrene Cross-linked 
polystyrene 
Cationic surface 
1.09 
Synthemax II ® 
(Low and High 
Concentration) 
Corning 125-212 Polystyrene Synthemax II ® 1.02 
Cytodex ITM GE Healthcare 60-87 Dextran Positively 
charged N,N-
diethylaminoethy
l groups 
1.03 
 
Table 2 - List of antibodies used for immunocytochemistry. 
Reactivity Antibody Host Company Code 
p75NTR IgG polyclonal Rabbit Millipore ab1554 
Fibronectin IgG monoclonal Mouse Sigma F6140 
Nestin IgG monoclonal Mouse Millipore MAB5326 
S100β IgG polyclonal Rabbit Dako Z0311 
GFAP IgG polyclonal Rabbit Dako Z0334 
β III Tubulin IgG monoclonal Mouse Sigma T8660 
CD90 IgG monoclonal Mouse Millipore MAB1406 
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Rabbit IgG (H+L) IgG DyLight 594 Goat Thermo Scientific 35560 
Mouse IgG (H+L) IgG DyLight 488 Goat Thermo Scientific 35510 
 
Table 3 - List of Primers used for qRT-PCR. 
Biomarker Description NCBI Accession QuantiTect Primer 
Assay 
Catalog Number 
p75NTR Glial Marker NM_002507 Hs_NFGR_1_SG QT00056756 
S100β Glial Marker NM_006272 Hs_S100B_1_SG QT00059164 
GFAP Glial Marker NM_001131019 Hs_GFAP_1_SG QT00081151 
Nestin Neural stem cell 
marker 
NM_006617 Hs_NES_1SG QT00235781 
β-III-tubulin Neural differentiation 
marker 
NM_006086 Hs_TUBB3_vb.1_SG QT02399950 
Fibronectin Cell adhesion marker NM_002026 Hs_FN1_1_SG QT00038024 
CD34 Negative MSC 
Marker 
NM_001773 Hs_CD34_1_SG QT00998284 
CD45 Negative MSC 
Marker 
NM_002838 Hs_PTPRC_1_SG QT00028791 
CD73 MSC Marker NM_002526 Hs_NT5E_1_SG QT00027279 
CD90 MSC Marker NM_001311160 Hs_THY1_1_SG QT00023569 
CD105 MSC Marker NM_00118 Hs_ENG_1SG QT00013335 
KDR Endothelial Cell 
Marker 
NM_002253 Hs_KDR_1_SG QT00069818 
Sox9 Chrondrogenic 
Marker 
NM_000346 Hs_SOX9_1_SG QT00001498 
Runx2 Osteogenic Marker NM_001015051 Hs_RUNX2_1_SG QT00020517 
SPP1 Osteogenic Marker NM_000582 Hs_SPP1_1_SG QT01008798 
PPARγ Adipogenic Marker NM_005037 Hs_PPARG_1_SG QT00029841 
β-actin Housekeeping gene NM_001101 Hs_ACTB_2_SG QT01680476 
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Figure Legends 
Figure 1 - Growth and phenotype of PA5 hOMCs on monolayer culture. (A) Cell growth was 
quantified using the CCK-8 viability reagent for 7 days. (B) Brightfield image of cells in culture. Cells 
stained positive for (C) p75NTR, (D) S100β, (E) GFAP, (F) β-III tubulin, (G) nestin, (H) fibronectin, 
and CD90 (I). Cell nuclei were counterstained with Hoechst (blue). Data is represented as mean±SEM, 
n = 3. (Scale bar =400μm). 
 
Figure 2 - PA5 hOMCs were grown on microcarriers in 96-well plates for 7 days on 10 different 
microcarriers. (A) Growth curve showing viable cells/well obtained through measurements of 
metabolite activity using the CCK-8 viability reagent. (B) Total viable cell/well achieved for each 
microcarrier on day 1. (C) Total viable cell/well achieved for each microcarrier on day 7. Data 
represented as mean ± SEM, n=3. Three independent repeats were performed for each condition. 
Significant differences were noted with (*) for p<0.05. 
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Figure 3– PA5 hOMCs were grown on Plastic L, Synthemax II LC, Collagen, Plastic, PronectinF and 
Plastic Plus microcarriers for 7 days with 50% media change every 2 days and using an initial seeding 
density of 6000 cells/cm2. Viable cell concentration (A) and cell viability (B) were measured. 
Metabolite analysis for glucose (C), lactate (D), and ammonium (E) were performed. (F) Expression of 
p75NTR, S100β, GFAP, β-III tubulin, nestin and fibronectin by PA5 hOMCs grown on Plastic L, 
Synthemax II LC, Collagen, Plastic, PronectinF and Plastic Plus, assessed through RT-qPCR on day 7. 
PA5 hOMCs before seeding were used as a reference. Data represented as mean ± SEM, n = 3. Three 
independent repeats were performed for each condition. Significant differences were noted with (*) for 
p<0.05. 
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Figure 4- Comparison of PA5 hOMCs growth on Plastic and Plastic Plus microcarriers, in spinner 
flasks for 7 days. (A) Viable cell concentration (cells/mL) and cell viability was measured via 
haemocytometer counts. Metabolite analysis was performed to determine concentration of (B) glucose 
(mM), (C) lactate (mM) and (D) ammonium (mM). (E) Representative images of cells on Plastic and 
Plastic Plus microcarriers, for each day of sample. Hoechst was used as a nucleic dye. (F) 
Representative bright field pictures of PA5 cells before and after harvest from Plastic and Plastic Plus 
microcarriers. Data is presented as mean ± SEM, n=3. Three independent runs were performed for each 
spinner flask condition. Significant differences were noted with (*) for p<0.05. Scale bar = 200 µm. 
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Figure 5 – Expression of p75NTR, GFAP, S100β (glial markers), β-III tubulin, nestin (neural markers), 
fibronectin (fibroblastic marker) after 7 days of growth of PA5 hOMCs on Plastic, Plastic Plus 
microcarriers under stirred suspension cultures in spinner flasks. 
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Figure 6 - The expression of p75NTR, GFAP, S100β (glial markers), β-III tubulin, nestin (neural 
markers), fibronectin (fibroblastic marker), CD90, CD105, CD73 (positive MSCs markers), CD34, 
CD45 (negative MSCs markers), PPARg (adipogenesis marker), SPP1, Runx2 (osteogenesis markers), 
Sox9 (chondrogenesis marker) and VEGFR2 (endothelial cell marker). (A) Heat map for gene 
expression variation relative to cells before seeding. (B) Values of expression relative to cells before 
seeding. NG108-15 co-culture assay to assess the potential for neural regeneration of PA5 hOMCs. F7 
Schwann cells were used as a positive control, and NG108-15 neurons only were used as negative 
control. (C) Representative images used to quantify neurite outgrowth. (D) Average neurite length, (E) 
maximum neurite length (F) average neurite per neuron, were higher for Plastic and especially Plastic 
Plus microcarriers (scale bar=400 µm). Data represented as mean ± SEM (n=3). Three independent 
runs were performed for each spinner flask condition. Significant differences were noted with (*) for 
p<0.05. 
 
 
